Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections
About this trial
This is an interventional treatment trial for Skin Diseases, Infectious focused on measuring Complicated Skin Infections, Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Cephalosporin
Eligibility Criteria
Inclusion Criteria: Diagnosis of an infection consistent with complicated skin and skin structure infections. Exclusion Criteria: Known or suspected hypersensitivity to any study medication or other related anti-infective medication Any known or suspected condition or concurrent treatment contraindicated by the prescribing information Previous enrollment in this study Treatment with any investigational drug within 30 days before enrollment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Vancomycin plus Ceftazidime
Ceftobiprole medocaril
Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d